-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) PT Lowered to $83 at BofA Securities
-
-
-
-
-
-
-
CRISPR Therapeutics reports early zugo-cel results in autoimmune diseases
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) PT Raised to $50 at RBC Capital
-
-
-
-
-
-
-
Intellia stock tumbles after pausing gene therapy trials on safety concerns
-
-
-
-
-
-
-
Sam Altman Brain Chip Venture Is Mulling Gene Therapy Approach - Bloomberg
-
-
-
-
-
-
-
Clear Street Downgrades CRISPR Therapeutics (CRSP) to Hold
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) gains on continued chatter
-
430,619 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

